Hanmi

Aptose Reports Results for the Fourth Quarter and Full Year 2023

Retrieved on: 
Tuesday, March 26, 2024
Indian stock exchange, Absorption, Plasma, Exercise, Hanmi Pharmaceutical, AML, BID, Patient, APS, SAN, Venetoclax, G1, VEN, FLT3, EHA, LUX, Acute myeloid leukemia, Trial of the century, TUS, TSX, Hanmi, Azacitidine, G3, Pharmaceutical industry

This included 736,842 Common Shares and warrants pursuant to a full exercise by the underwriter of its over-allotment option.

Key Points: 
  • This included 736,842 Common Shares and warrants pursuant to a full exercise by the underwriter of its over-allotment option.
  • Total gross proceeds from the public offering were approximately $9.7 million before deducting underwriting costs, placement agent commissions and other offering-related expenses.
  • Private Placement – On January 31, 2024, Aptose closed a US $4 million private placement of common shares with strategic partner Hanmi Pharmaceutical.
  • Luxeptinib G3 Evaluation Completed – During 2023 and early 2024, clinical evaluation of the new generation 3 (G3) formulation of luxeptinib (LUX) was completed.

Hanmi Bank Celebrates Grand Opening of Its New Dublin, CA Branch with Local Community

Retrieved on: 
Wednesday, December 6, 2023
City, Silicon, Hanmi, SBA, HAFC, Korean Americans, Treasury, Hanmi Bank, Nightclub

LOS ANGELES, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Hanmi Financial Corporation (Nasdaq: HAFC) (“Hanmi”), the holding company for Hanmi Bank, today announced it hosted a community grand opening event on Tuesday, December 5th, to commemorate its new branch in Dublin, CA.

Key Points: 
  • LOS ANGELES, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Hanmi Financial Corporation (Nasdaq: HAFC) (“Hanmi”), the holding company for Hanmi Bank, today announced it hosted a community grand opening event on Tuesday, December 5th, to commemorate its new branch in Dublin, CA.
  • Melissa Hernandez, Mayor of Dublin , local leaders from the Korean American community, and clients of the bank joined the celebration.
  • The 3,070 square foot branch is in the East Bay, located at 7912 Dublin Blvd, Dublin.
  • Choi began her banking career in 2006 and joined Hanmi in 2015 as the service manager for the Silicon Valley branch.

AffaMed Therapeutics Announces Clinical Trial Application Approval in Mainland China for Risuteganib (Luminate®) First-in-Class Candidate for the Treatment of Intermediate Dry AMD

Retrieved on: 
Monday, September 25, 2023
Hanmi, AMD, Macular degeneration, CTA, Dry, Patient, National Medical Products Administration, Therapy, Safety, Pharmaceutical industry

Under the CTA approval, AM011 is expected to become the first product in China to enter Phase 3 development for the treatment of Dry AMD.

Key Points: 
  • Under the CTA approval, AM011 is expected to become the first product in China to enter Phase 3 development for the treatment of Dry AMD.
  • In December 2021, AffaMed Therapeutics entered into a licensing agreement with Hanmi Pharmaceutical Co., Ltd. ("Hanmi") for the manufacturing, development and commercialization of Risuteganib (Luminate®) in Greater China (mainland China, Hong Kong, Taiwan and Macau).
  • Dr. Dayao Zhao, CEO of AffaMed commented: " To date there is no approved and effective treatment in China for patients suffering from Dry AMD which represents the vast majority of the AMD patient population.
  • We are looking forward to bringing this innovative treatment to Dry AMD patients in Greater China as soon as possible."

SHAREHOLDER ALERT: Morris Kandinov Investigating EBS, JRVR, EGIO, and HAFC; Shareholders are Encouraged to Contact the Firm

Retrieved on: 
Wednesday, September 20, 2023
Hanmi, Emergent BioSolutions, Johnson & Johnson, Akamai Techs., Inc. v. Limelight Networks, Inc., Central District, Hanmi Pharmaceutical, COVID-19, Emergent, History, AstraZeneca, Public sector banks in India, Complaint, District court, Settlement, Edgio, Advertising, SAN, Growth, Bacteria, FDA, Pharmaceutical industry

Morris Kandinov is investigating Emergent BioSolutions Inc. regarding possible breaches of fiduciary duties and other violations of law on behalf of shareholders.

Key Points: 
  • Morris Kandinov is investigating Emergent BioSolutions Inc. regarding possible breaches of fiduciary duties and other violations of law on behalf of shareholders.
  • Morris Kandinov reminds investors that it is investigating James River Group Holdings regarding possible breaches of fiduciary duties and other violations of law on behalf of shareholders.
  • Morris Kandinov reminds investors that it is investigating Hanmi Financial Corporation regarding possible breaches of fiduciary duties and other violations of law, including securities claims on behalf of shareholders.
  • Concerned shareholders are encouraged to contact Leo Kandinov to learn more:
    Morris Kandinov LLP is a national law firm that specializes in recovering investment losses and protecting stockholder rights.

Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical

Retrieved on: 
Wednesday, September 6, 2023
TP53, Toronto Stock Exchange, TUS, Hope, Mutation, Consultant, Acute myeloid leukemia, AML, Hanmi Pharmaceutical, Patient, SAN, FLT3, TSX, Safety, Pharmaceutical industry, Security (finance), Hanmi, Share (finance)

Under the terms of the strategic investment, Hanmi purchased each Share at a price of $4.488, representing a premium over Aptose’s common stock price.

Key Points: 
  • Under the terms of the strategic investment, Hanmi purchased each Share at a price of $4.488, representing a premium over Aptose’s common stock price.
  • Aptose has granted Hanmi certain rights pursuant to an investor rights agreement, including registration rights, pre-emptive rights, information rights and the right to appoint non-executive consultants.
  • The closing of the second tranche for up to $4 million or a maximum of 19.99 percent ownership interest will be triggered upon Aptose achieving, prior to July 1, 2024, certain manufacturing and data milestones related to tuspetinib.
  • “We are grateful to our valued partner Hanmi Pharmaceutical for this investment and their confidence in our strategic direction," said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer.

SHAREHOLDER ALERT: Morris Kandinov Investigating FATE, HAFC, PEGA, and CVNA; Shareholders are Encouraged to Contact the Firm

Retrieved on: 
Monday, August 21, 2023
Hanmi, Central District, Hanmi Pharmaceutical, Public sector banks in India, Complaint, Destiny, District court, Settlement, SAN, Therapy, Pharmaceutical industry, Carvana

Morris Kandinov is investigating Fate Therapeutics, Inc. regarding possible breaches of fiduciary duties and other violations of law, including securities claims on behalf of shareholders.

Key Points: 
  • Morris Kandinov is investigating Fate Therapeutics, Inc. regarding possible breaches of fiduciary duties and other violations of law, including securities claims on behalf of shareholders.
  • Morris Kandinov is investigating Hanmi Financial Corporation regarding possible breaches of fiduciary duties and other violations of law, including securities claims on behalf of shareholders.
  • Morris Kandinov is investigating Pegasystems regarding possible breaches of fiduciary duties and other violations of law on behalf of shareholders.
  • Morris Kandinov is investigating Carvana Co. regarding possible breaches of fiduciary duties and other violations of law, including securities claims on behalf of shareholders.

SHAREHOLDER ALERT: Morris Kandinov Investigating HAFC, CVNA, PEGA, and NLTX; Shareholders are Encouraged to Contact the Firm

Retrieved on: 
Wednesday, August 16, 2023
Hanmi, Central District, Hanmi Pharmaceutical, Public sector banks in India, Complaint, District court, Settlement, SAN, Advertising, Carvana

Morris Kandinov is investigating Hanmi Financial Corporation regarding possible breaches of fiduciary duties and other violations of law, including securities claims on behalf of shareholders.

Key Points: 
  • Morris Kandinov is investigating Hanmi Financial Corporation regarding possible breaches of fiduciary duties and other violations of law, including securities claims on behalf of shareholders.
  • Morris Kandinov is investigating Carvana Co. regarding possible breaches of fiduciary duties and other violations of law, including securities claims on behalf of shareholders.
  • Morris Kandinov is investigating Pegasystems regarding possible breaches of fiduciary duties and other violations of law on behalf of shareholders.
  • Concerned shareholders are encouraged to contact Leo Kandinov to learn more:
    Morris Kandinov LLP is a national law firm that specializes in recovering investment losses and protecting stockholder rights.

DxVx appoints Yong Gu Lee as new CEO and Kevin Kwon as the new president

Retrieved on: 
Tuesday, May 16, 2023
Vaccine, Molecular biology, Hanmi, Hanyang University, Broad Institute, RA, Diabetes, Biochemistry, Catholic higher education, Pharming, National university, RXR Realty, Haemophilus influenzae, Korea University, Ministry of Food and Drug Safety, Cancer, Lead, Medicine, Research, Multimedia, MIT, Pierre and Marie Curie University, Veteran, Harvard University, Bangladesh Technical Education Board, Harvard Medical School, Certification, Organization, Ministry, Core Group, CLIA, Acquisition, Cervical cancer, Seoul National University, Institut Pasteur Korea, Growth, FDA, IND, Pharmaceutical industry, Management, Food

SEOUL, South Korea, May 16, 2023 /PRNewswire/ -- DxVx announced on the 16th, the board of directors appointed Yong Gu Lee as the new CEO and Kevin Kwon, the former head of global business division at Hanmi Pharm.Co.,Ltd., as the new president. Drawing on the expertise of sales veterans who have more than 30 years of experience, the company plans to actively reorganize the global sales networks, launch new products and further enhance its capabilities to get global approvals for new drugs.

Key Points: 
  • SEOUL, South Korea, May 16, 2023 /PRNewswire/ -- DxVx announced on the 16th, the board of directors appointed Yong Gu Lee as the new CEO and Kevin Kwon, the former head of global business division at Hanmi Pharm.Co.,Ltd., as the new president.
  • The new CEO, Yong Gu Lee, graduated from Hanyang University.
  • Co., Ltd., managing director of the healthcare business division at Beijing Medi'Care Co., Ltd and vice president of the COREE Group.
  • New president Kevin Kwon will be appointed as a board director from a shareholders' meeting.

STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Hanmi Financial Corporation and Encourages Long-Term HAFC Stockholders to Contact the Firm

Retrieved on: 
Monday, March 6, 2023
Public sector banks in India, HAFC, Complaint, Book, Acquisition, Financial adviser, Hanmi

PHILADELPHIA, March 06, 2023 (GLOBE NEWSWIRE) -- Investor protection law firm Kaskela Law LLC announces that it is investigating Hanmi Financial Corporation (“Hanmi” or the “Company”) (NASDAQ: HAFC) on behalf of the Company’s long-term stockholders.

Key Points: 
  • PHILADELPHIA, March 06, 2023 (GLOBE NEWSWIRE) -- Investor protection law firm Kaskela Law LLC announces that it is investigating Hanmi Financial Corporation (“Hanmi” or the “Company”) (NASDAQ: HAFC) on behalf of the Company’s long-term stockholders.
  • Current Hanmi stockholders who purchased or acquired shares of the Company’s stock prior to January 1, 2020 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.
  • Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis.
  • For additional information about Kaskela Law LLC please visit www.kaskelalaw.com .

SHAREHOLDER ALERT: Kaskela Law LLC Announces Stockholder Investigation of Hanmi Financial Corporation (NASDAQ: HAFC) and Encourages Long-Term HAFC Stockholders to Contact the Firm

Retrieved on: 
Monday, December 12, 2022
Public sector banks in India, Acquisition, Complaint, Book, HAFC, Financial adviser, Hanmi

PHILADELPHIA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Hanmi Financial Corporation (“Hanmi” or the “Company”) (NASDAQ: HAFC) on behalf of the Company’s long-term investors.

Key Points: 
  • PHILADELPHIA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Hanmi Financial Corporation (“Hanmi” or the “Company”) (NASDAQ: HAFC) on behalf of the Company’s long-term investors.
  • Recently an amended shareholder complaint was filed against Hanmi in federal court on behalf of investors who purchased shares of the Company’s common stock between August 9, 2018 and April 30, 2020.
  • Current Hanmi stockholders who purchased or acquired shares of the Company’s stock prior to January 1, 2020 are encouraged to contact Kaskela Law LLC (Adrienne Bell, Esq.)
  • Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation.